ĀÜĄņĀŅĀ×

Stacie is the president of FBRI. Prior to this position, she was the senior director of science programs for the Fidelity Foundations. In 2005, Stacie served as the project manager and senior analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Stacie was a senior scientist at Cell Press for the journal Neuron. Before joining Cell Press, Stacie was a postdoctoral research fellow at Childrenā€™s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the program in neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Stacie was actively involved in undergraduate teaching, winning six teaching awards.

Stacie received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimerā€™s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Aratome, Atalanta, Eikonizo, RBNC, Sironax, and Target ALS; and serves as a member of the Scientific Advisory Boards for Denali Therapeutics, the Indian Institute of Scienceā€™s Centre for Brain Research and the UK Dementia Research Institute. She previously served as a founding member of the Board of Directors for Denali Therapeutics (NASDAQ: DNLI); as well as a member of the Board of Directors for Annexon Biosciences (NASDAQ: ANNX), BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix, Syllable Life Sciences (acquired by RBNC), and Q-State Biosciences.